Evidence map›Paper›PMID 42256204›Full record

ArticleMolecular therapy. Oncology2026

Differentiation-inducing triiodothyronine enhances chemotherapy and suppresses post-treatment tumor regrowth in medulloblastoma.

Yijun Yang, Rebecca Ronsley, Lindsay Kilburn, Albert Kim, Robert J Wechsler-Reya, Zeng-Jie Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yijun YangNuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA 19111, USA.
Rebecca RonsleyThe Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA.
Lindsay KilburnCenter for Cancer and Blood Disorders, Children's National Hospital, Washington, DC 20816, USA.
Albert KimDepartment of Medical Engineering, University of South Florida, Tampa, FL 33620, USA.
Robert J Wechsler-ReyaDepartment of Neurology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Zeng-Jie YangNuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Temple Health System, Philadelphia, PA 19111, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medulloblastoma (MB), the most common malignant pediatric brain tumor, is treated with intensive multimodal regimens that cause substantial long-term toxicity and fail to prevent recurrence in up to 30% of patients. We investigated triiodothyronine (T3), an FDA-approved thyroid hormone, as a differentiation-based therapeutic strategy for MB. Using a Sonic Hedgehog (SHH)-driven mouse model, two patient-derived xenografts (SHH and group 3), and drug-resistant TP53-mutant MB cells, we found that T3 and cytotoxic chemotherapy suppress tumor growth through complementary biological mechanisms: T3 promotes terminal differentiation of tumor cells, whereas cyclophosphamide (CTX) and irinotecan (CPT-11) induce caspase-3-dependent apoptosis.

Indexed as

chemotherapy resistancecombined treatmentcytotoxic drugsdifferentiation therapydrug repurposingmedulloblastomaneuronal differentiationtriiodothyroninetumor regrowthtumor relapse

Identifiers

PMID42256204
PMCPMC13233753

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.